In addition, disruption of TP53 by CRISPR/Cas9-mediated gene editing enhanced the inhibitory effects of BUB1B knockdown on MOLM-13 proliferation, further implicating the kinase as a potential target in TP53-altered AML cells (Fig. 6g–i). Here, TP53 is linked to acute myeloid leukemia.